Acquisition of PSR Group BV, a specialist orphan drug CRO, for consideration of up to €5.7 million
Placing to raise £2.9 million
- Acquisition moves Ergomed towards leadership in orphan drug development services
- PSR’s specialist orphan drug development business will complement Ergomed’s existing strong expertise in this area
- PSR will expand Ergomed’s services…
London, UK, 27 September 2017
Boryung Pharmaceutical Co.Ltd licenses PeproStat™ and ReadyFlow™ for commercialisation in South Korea
Ergomed to receive an upfront and future milestone payments as well as double-digit share of product sales
Deal driven by British innovation in the treatment of surgical bleeding with multi-million dollar potential
London, UK / Seoul, Republic…
London, UK, 24 July 2017
– Top line results expected in Q4 2017, six months earlier than anticipated.
– Faster than expected recruitment reflects Ergomed’s strong CRO capabilities.
London, UK – 24 July 2017: Ergomed plc (LSE: ERGO) (‘Ergomed’ or the ‘Company’), a specialised pharmaceutical services and drug development company, today announces that recruitment has been completed ahead of schedule in…
London, UK, 21 June 2017
London, UK – 21 June 2017: Ergomed plc (LSE: ERGO) (‘Ergomed’ or the ‘Company’), a company dedicated to the provision of specialised services to the pharmaceutical industry and the development of new drugs, today announces that its Phase IIb proof-of-concept study for PeproStat, Ergomed’s highly innovative new coagulant, or ‘haemostat’, for intraoperative…
London, UK, 16 June 2017
London, UK –16 June 2017: Ergomed plc (LSE: ERGO) (‘Ergomed’ or ‘the Company’), a company dedicated to the provision of specialised services to the pharmaceutical industry and the development of new drugs, today announces that all resolutions put to shareholders were duly passed at its Annual General Meeting held earlier today.
Page 1 of 1712345...10...»Last »